Gilig, Rocky Shann M.

HRN: 25-84-89  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/15/2025
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
03/15/2025
03/22/2025
IV
380mg
Q6H
PCAP C
Waiting Final Action 
03/17/2025
CEFTRIAXONE 1G (VIAL)
03/17/2025
03/23/2025
IV
700mg
OD
PCAP C
Waiting Final Action 
03/17/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
03/17/2025
03/23/2025
IV
105mg
Q24H
PCAP C
Waiting Final Action 
03/21/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
03/21/2025
03/27/2025
IVT
550mg
Q6
Sepsis
Waiting Final Action 
03/22/2025
MUPIROCIN 2%, 15G (TUBE)
03/22/2025
03/28/2025
TOPICAL
2%
TID
INFECTED IV SITE
Waiting Final Action 
03/23/2025
GENTAMICIN 40MG/ML, 2ML (AMP)
03/23/2025
03/29/2025
IV
38mg
OD
Sepsis
Waiting Final Action 
03/25/2025
CEFTRIAXONE 1G (VIAL)
03/25/2025
03/31/2025
IV
760
Q24
PCAP C
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: